NUPLAZID (pimavanserin tartrate)
Development Insights
Details
- Status
- Discontinued
- First Approved
- 2016-04-29
- Patent Cliff
- 2039
- Routes
- ORAL
- Dosage Forms
- TABLET, CAPSULE
NUPLAZID Approval History
What NUPLAZID Treats
4 FDA approvalsOriginally approved for its first indication in 2016 . Covers 4 distinct patient populations.
- Other (4)
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06068465 | TSL-CM-JSSPMFSL-Ⅲ | Ph 3 | completed | A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis |
| NCT02035553 results posted | ACP-103-019 | Ph 2 | completed | A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis |
| NCT01174004 results posted | ACP-103-020 | Ph 3 | completed | A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
NUPLAZID FDA Label Details
NUPLAZID Patents & Exclusivity
Patents (17 active)
Pro Intelligence Preview
Deep insights for NUPLAZID
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2039
- • 41 active patents
Trial Analysis
- • 3 total trials
- • Stage: Declining
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment